Early initiation of external beam radiotherapy (EBRT) increases the risk of long-term toxicity in patients undergoing intraoperative radiotherapy (IORT) as a boost for breast cancer;Erhöhtes risiko von spätfolgen bei zu kurzem intervall zwischen intraoperativem tumorbettboost und mammahomogenbestrahlung

Geburtshilfe und Frauenheilkunde

Volumn 68, Issue 7, 2008, Pages 729-733

  Blank, E ^a   Welzel, G ^a   Tome O ^a   Kraus Tiefenbacher, U ^a   Wenz, Frederik ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Boost; Breast cancer; Fibrosis; Intraoperative radiotherapy; Toxicity

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CHRONIC TOXICITY; EDEMA; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FIBROSIS; FOLLOW UP; HUMAN; HYPERPIGMENTATION; INTRAOPERATIVE PERIOD; LYMPHEDEMA; MAJOR CLINICAL STUDY; PATIENT SAFETY; RISK ASSESSMENT; SYSTEMIC THERAPY; TELANGIECTASIA; TISSUE INJURY; TOXICITY TESTING;

EID: 49649087682     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1038712     Document Type: Article

References (25)

1. Kraus-Tiefenbacher U, Bauer L, Kehrer T et al. Intraoperative radiotherapy (IORT) as a boost in patients with early-stage breast cancer - acute toxicity. Onkologie 2006; 29: 77-82
2. Kraus-Tiefenbacher U, Bauer L, Scheda A et al. Long-term toxicity of an intraoperative radiotherapy boost using low energy X-rays during breast-conserving surgery. Int J Radiat Oncol Biol Phys 2006; 66: 377-381
3. Kraus-Tiefenbacher U, Scheda A, Steil V et al. Intraoperative radiotherapy (IORT) for breast cancer using the Intrabeam system. Tumori 2005; 91: 339-345
4. Kraus-Tiefenbacher U, Steil V, Bauer L, Melchert F, Wenz F. A novel mobile device for intraoperative radiotherapy (IORT). Onkologie 2003; 26: 596-598
5. Reitsamer R, Sedlmayer F, Kopp M et al. The Salzburg concept of intraoperative radiotherapy for breast cancer: results and considerations. Int J Cancer 2006; 118: 2882-2887
6. Sauer R, Wenz F, Strnad V et al. [Partial breast irradiation after breast-conserving surgery for breast cancer.] Strahlenther Onkol 2005; 181: 417-423
7. Vaidya JS, Baum M, Tobias JS et al. Targeted intraoperative radiotherapy (TARGIT) yields very low recurrence rates when given as a boost. Int J Radiat Oncol Biol Phys 2006; 66: 1335-1338
8. Vaidya JS, Tobias JS, Baum M et al. Intraoperative radiotherapy for breast cancer. Lancet Oncol 2004; 5: 165-173
9. Intra M, Luini A, Gatti G et al. Surgical technique of intraoperative radiation therapy with electrons (ELIOT) in breast cancer: a lesson learned by over 1000 procedures. Surgery 2006; 140: 467-471
10. Vaidya JS, Tobias JS, Baum M et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Semin Radiat Oncol 2005; 15: 84-91
11. Veronesi U, Orecchia R, Luini A et al. Full-dose intraoperative radiotherapy with electrons during breast-conserving surgery: experience with 590 cases. Ann Surg 2005; 242: 101-106
12. Goldhirsch A, Wood W, Gelber R et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133-1144
13. LENT SOMA tables. Radiother Oncol 1995; 35: 17-60
14. Seegenschmiedt MH. Interdisciplinary documentation of treatment side effects in oncology. Present status and perspectives. Strahlenther Onkol 1998; 174: 25-29
15. Lilla C, Ambrosone CB, Kropp S et al. Predictive factors for late normal tissue complications following radiotherapy for breast cancer. Breast Cancer Res Treat 2007; 106: 143-150
16. Hoeller U, Tribius S, Kuhlmey A et al. Increasing the rate of late toxicity by changing the score? A comparison of RTOG/EORTC and LENT/SOMA scores. Int J Radiat Oncol Biol Phys 2003; 55: 1013-1018
17. Antonini N, Jones H, Horiot JC et al. Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. Radiother Oncol 2007; 82: 265-271
18. Bartelink H, Horiot JC, Poortmans P et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001; 345: 1378-1387
19. Vrieling C, Collette L, Fourquet A et al. The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC "boost vs. no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. Radiother Oncol 2000; 55: 219-232
20. Chen PY, Vicini FA, Benitez P et al. Long-term cosmetic results and toxicity after accelerated partial-breast irradiation: a method of radiation delivery by interstitial brachytherapy for the treatment of early-stage breast carcinoma. Cancer 2006; 106: 991-999
21. Shah NM, Tenenholz T, Arthur D et al. MammoSite and interstitial brachytherapy for accelerated partial breast irradiation: factors that affect toxicity and cosmesis. Cancer 2004; 101: 727-734
22. Herskind C, Schalla S, Hahn EW, Hover KH, Wenz F. Influence of different dose rates on cell recovery and RBE at different spatial positions during protracted conformal radiotherapy. Radiat Prot Dosimetry 2006; 122: 498-505
23. Herskind C, Steil V, Kraus-Tiefenbacher U, Wenz F. Radiobiological aspects of intraoperative radiotherapy (IORT) with isotropic low-energy X rays for early-stage breast cancer. Radiat Res 2005; 163: 208-215
24. Ott OJ, Schulz-Wendtland R, Uter W et al. Fat necrosis after conserving surgery and interstitial brachytherapy and/or external-beam irradiation in women with breast cancer. Strahlenther Onkol 2005; 181: 638-644
25. Wasser K, Schoeber C, Kraus-Tiefenbacher U et al. Early mammographic and sonographic findings after intraoperative radiotherapy (IORT) as a boost in patients with breast cancer. Eur Radiol 2007; 17: 1865-1874